BioStem Technologies Inc. (BSEM)
NASDAQ: BSEMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BSEM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $12.18M
- P/E (TTM)
- 0.72
- Forward P/E
- 2.19
- EPS (TTM)
- $0.88
- Dividend yield
- None
- 52-week range
- 0.5347 – 8.40
- Day range
- 0.5347 – 0.71
- Volume / Avg
- 254.19K / 194.93K
- Beta
- —
- Shares outstanding
- 19.18M
52-week range
BSEM stock today
Shares of BioStem Technologies (BSEM) finished lower on Nov 20 at $0.6351, a drop of 10.23% or $0.0724 per share, versus the S&P 500's 3.70% decline. Shares are 92.4% below their 52-week high of $8.40, set on Jan 28, 2026 and 18.8% above the 52-week low of $0.5347, near the bottom of the past year's range. BSEM is down 83.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 84.0%.
BioStem Technologies trades at 0.7x its trailing twelve-month earnings per share of $0.88. Its forward P/E of 2.2x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About BioStem Technologies
Company profileBioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a human connective tissue matrix compromised of amniotic tissue intended for wound covering; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Headquarters
- Fort Lauderdale, FL
- Employees
- 73
- Website
- biostemtechnologies.com
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$7.00+1002.19%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.64 vs $-0.43
- Surprise
- -48.84%
BSEM news
All BSEM news- BioStem Technologies, Inc. Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue GuidanceNasdaq
- BioStem (BSEM) Q3 2026 Earnings Call TranscriptNasdaq
- BioStem Technologies to Host Third Quarter 2026 Financial Results Conference Call on November 12, 2026GlobeNewswire
- BioStem Technologies’ CEO and COO Invest $1 Million in Cash Through Exercise of Stock OptionsGlobeNewswire
BioStem Technologies peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BCDABioCardia Inc. | 0.785 | +1.60% | $11.88M | vs BSEM |
| PASGPassage Bio Inc. | 3.92 | +11.68% | $12.61M | vs BSEM |
| DYAIDyadic International Inc. | 0.287 | -7.66% | $11.51M | vs BSEM |
| ABOSAcumen Pharmaceuticals Inc. | 0.1865 | -3.52% | $13.49M | vs BSEM |
| PLURPluri Inc. | 0.94 | -3.07% | $13.51M | vs BSEM |
| ESLAEstrella Immunopharma Inc. | 0.321 | -5.70% | $14.11M | vs BSEM |
| TCRXTScan Therapeutics Inc. | 0.1459 | +2.24% | $9.89M | vs BSEM |
| ATYRaTyr Pharma Inc. | 3.82 | +3.52% | $9.74M | vs BSEM |
Indexes, lists and sector
BioStem Technologies stock FAQ
What is BioStem Technologies's stock price today?
BSEM last traded at $0.6351 as of Nov 20, 4:00 PM EST, down 10.23% on the day. Prices are delayed at least 15 minutes.
What is BSEM's P/E ratio?
BSEM trades at a trailing P/E ratio of 0.72 and a forward P/E of 2.19.
What is the BSEM 52-week high?
The 52-week high for BSEM is $8.40 and the 52-week low is $0.5347. The stock is currently 92.4% below its high.